摘要
Gastrointestinal stromal tumors(GISTs) are the most common mesenchymal tumors located in the alimentary tract. Its usual manifestation is gastrointestinal bleeding. However, small asymptomatic lesions are frequently detected as incidental finding. Characteristically, most GISTs(> 95%) are positive for the KIT protein(CD117) by IHC staining and approximately 80%-90% of GISTs carry a mutation in the c-KIT or PDGFRA genes. Mutational analysis should be performed when planning adjuvant and neoadjuvant therapy, due to its possible resistance to conventional treatment. The arise of tyrosine kinase inhibitor has supposed a revolution in GISTs treatment being useful as adjuvant, neoadjuvant or recurrence disease treatment. That is why a multidisciplinary approach to this disease is required. The correct characterization of the tumor at diagnosis(the diagnosis of recurrences and the evaluation of the response to treatment with tyrosine kinase inhibitors) is fundamental for facing these tumors and requires specialized Endoscopist, Radiologists and Nuclear Medicine Physician. Surgery is the only potentially curative treatment for suspected resectable GIST. In the case of high risk GISTs, surgery plus adjuvantImatinib-Mesylate for 3 years is the standard treatment. Neoadjuvant imatinib-mesylate should be considered to shrink the tumor in case of locally advanced primary or recurrence disease, unresectable or potentially resectable metastasic tumors, and potentially resectable disease in complex anatomic locations to decrease the related morbidity. In the case of Metastatic GIST under Neoadjuvant treatment, when there are complete response, stable disease or limited disease progression, complete cytoreductive surgery could be a therapeutic option if feasible.
Gastrointestinal stromal tumors(GISTs) are the most common mesenchymal tumors located in the alimentary tract. Its usual manifestation is gastrointestinal bleeding. However, small asymptomatic lesions are frequently detected as incidental finding. Characteristically, most GISTs(> 95%) are positive for the KIT protein(CD117) by IHC staining and approximately 80%-90% of GISTs carry a mutation in the c-KIT or PDGFRA genes. Mutational analysis should be performed when planning adjuvant and neoadjuvant therapy, due to its possible resistance to conventional treatment. The arise of tyrosine kinase inhibitor has supposed a revolution in GISTs treatment being useful as adjuvant, neoadjuvant or recurrence disease treatment. That is why a multidisciplinary approach to this disease is required. The correct characterization of the tumor at diagnosis(the diagnosis of recurrences and the evaluation of the response to treatment with tyrosine kinase inhibitors) is fundamental for facing these tumors and requires specialized Endoscopist, Radiologists and Nuclear Medicine Physician. Surgery is the only potentially curative treatment for suspected resectable GIST. In the case of high risk GISTs, surgery plus adjuvantImatinib-Mesylate for 3 years is the standard treatment. Neoadjuvant imatinib-mesylate should be considered to shrink the tumor in case of locally advanced primary or recurrence disease, unresectable or potentially resectable metastasic tumors, and potentially resectable disease in complex anatomic locations to decrease the related morbidity. In the case of Metastatic GIST under Neoadjuvant treatment, when there are complete response, stable disease or limited disease progression, complete cytoreductive surgery could be a therapeutic option if feasible.
引文
1 S?reide K,Sandvik OM,S?reide JA,Giljaca V,Jureckova A,Bulusu VR.Global epidemiology of gastrointestinal stromal tumours(GIST):A systematic review of population-based cohort studies.Cancer Epidemiol 2016;40:39-46[PMID:26618334DOI:10.1016/j.canep.2015.10.031]
2 Nilsson B,Bümming P,Meis-Kindblom JM,Odén A,Dortok A,Gustavsson B,Sablinska K,Kindblom LG.Gastrointestinal stromal tumors:the incidence,prevalence,clinical course,and prognostication in the preimatinib mesylate era--a populationbased study in western Sweden.Cancer 2005;103:821-829[PMID:15648083 DOI:10.1002/cncr.20862]
3 Ma GL,Murphy JD,Martinez ME,Sicklick JK.Epidemiology of gastrointestinal stromal tumors in the era of histology codes:results of a population-based study.Cancer Epidemiol Biomarkers Prev2015;24:298-302[PMID:25277795 DOI:10.1158/1055-9965.epi-14-1002]
4 Harlan LC,Eisenstein J,Russell MC,Stevens JL,Cardona K.Gastrointestinal stromal tumors:treatment patterns of a populationbased sample.J Surg Oncol 2015;111:702-707[PMID:25900896DOI:10.1002/jso.23879]
5 De Matteo RP,Lewis JJ,Leung D,Mudan SS,Woodruff JM,Brennan MF.Two hundred gastrointestinal stromal tumors:recurrence patterns and prognostic factors for survival.Ann Surg2000;231:51-58[PMID:10636102]
6 Kindblom LG,Remotti HE,Aldenborg F,Meis-Kindblom JM.Gastrointestinal pacemaker cell tumor(GIPACT):gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of Cajal.Am J Pathol 1998;152:1259-1269[PMID:9588894]
7 Sircar K,Hewlett BR,Huizinga JD,Chorneyko K,Berezin I,Riddell RH.Interstitial cells of Cajal as precursors of gastrointestinal stromal tumors.Am J Surg Pathol 1999;23:377-389[PMID:10199467]
8 Fletcher CD,Berman JJ,Corless C,Gorstein F,Lasota J,Longley BJ,Miettinen M,O’Leary TJ,Remotti H,Rubin BP,Shmookler B,Sobin LH,Weiss SW.Diagnosis of gastrointestinal stromal tumors:A consensus approach.Hum Pathol 2002;33:459-465[PMID:12094370]
9 Rubin BP.Gastrointestinal stromal tumours:an update.Histopathology 2006;48:83-96[PMID:16359540 DOI:10.1111/j.1365-2559.2005.02291.x]
10 Demetri GD,von Mehren M,Blanke CD,Van den Abbeele AD,Eisenberg B,Roberts PJ,Heinrich MC,Tuveson DA,Singer S,Janicek M,Fletcher JA,Silverman SG,Silberman SL,Capdeville R,Kiese B,Peng B,Dimitrijevic S,Druker BJ,Corless C,Fletcher CD,Joensuu H.Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.N Engl J Med 2002;347:472-480[PMID:12181401 DOI:10.1056/NEJMoa020461]
11 Tran T,Davila JA,El-Serag HB.The epidemiology of malignant gastrointestinal stromal tumors:an analysis of 1,458 cases from1992 to 2000.Am J Gastroenterol 2005;100:162-168[PMID:15654796 DOI:10.1111/j.1572-0241.2005.40709.x]
12 Miettinen M,Sobin LH,Lasota J.Gastrointestinal stromal tumors of the stomach:a clinicopathologic,immunohistochemical,and molecular genetic study of 1765 cases with long-term follow-up.Am J Surg Pathol 2005;29:52-68[PMID:15613856]
13 Miettinen M,Makhlouf H,Sobin LH,Lasota J.Gastrointestinal stromal tumors of the jejunum and ileum:a clinicopathologic,immunohistochemical,and molecular genetic study of 906 cases before imatinib with long-term follow-up.Am J Surg Pathol 2006;30:477-489[PMID:16625094]
14 Robb WB,Bruyere E,Amielh D,Vinatier E,Mabrut JY,Perniceni T,Piessen G,Mariette C;FREGAT Working Group--FRENCH.Esophageal gastrointestinal stromal tumor:is tumoral enucleation a viable therapeutic option?Ann Surg 2015;261:117-124[PMID:25062398 DOI:10.1097/sla.0000000000000505]
15 Heinrich MC,Corless CL.Gastric GI stromal tumors(GISTs):the role of surgery in the era of targeted therapy.J Surg Oncol 2005;90:195-207;discussion 207[PMID:15895440 DOI:10.1002/jso.20230]
16 Frankel TL,Chang AE,Wong SL.Surgical options for localized and advanced gastrointestinal stromal tumors.J Surg Oncol 2011;104:882-887[PMID:21381037 DOI:10.1002/jso.21892]
17 Martin-Broto J,Martinez-Marín V,Serrano C,Hindi N,LópezGuerrero JA,Bisculoa M,Ramos-Asensio R,Vallejo-Benítez A,Marcilla-Plaza D,González-Cámpora R.Gastrointestinal stromal tumors(GISTs):SEAP-SEOM consensus on pathologic and molecular diagnosis.Clin Transl Oncol 2017;19:536-545[PMID:27943096 DOI:10.1007/s12094-016-1581-2]
18 Pink D,Schoeler D,Lindner T,Thuss-Patience PC,Kretzschmar A,Knipp H,Vanhoefer U,Reichardt P.Severe hypoglycemia caused by paraneoplastic production of IGF-II in patients with advanced gastrointestinal stromal tumors:a report of two cases.JClin Oncol 2005;23:6809-6811[PMID:16170199 DOI:10.1200/jco.2005.02.4828]
19 Maynard MA,Marino-Enriquez A,Fletcher JA,Dorfman DM,Raut CP,Yassa L,Guo C,Wang Y,Dorfman C,Feldman HA,Frates MC,Song H,Jugo RH,Taguchi T,Hershman JM,Larsen PR,Huang SA.Thyroid hormone inactivation in gastrointestinal stromal tumors.N Engl J Med 2014;370:1327-1334[PMID:24693892 DOI:10.1056/NEJMoa1308893]
20 Gasparotto D,Rossi S,Bearzi I,Doglioni C,Marzotto A,Hornick JL,Grizzo A,Sartor C,Mandolesi A,Sciot R,DebiecRychter M,Dei Tos AP,Maestro R.Multiple primary sporadic gastrointestinal stromal tumors in the adult:an underestimated entity.Clin Cancer Res 2008;14:5715-5721[PMID:18779314DOI:10.1158/1078-0432.Ccr-08-0622]
21 Miettinen M,Fetsch JF,Sobin LH,Lasota J.Gastrointestinal stromal tumors in patients with neurofibromatosis 1:a clinicopathologic and molecular genetic study of 45 cases.Am JSurg Pathol 2006;30:90-96[PMID:16330947]
22 Carney JA.Gastric stromal sarcoma,pulmonary chondroma,and extra-adrenal paraganglioma(Carney Triad):natural history,adrenocortical component,and possible familial occurrence.Mayo Clin Proc 1999;74:543-552[PMID:10377927 DOI:10.4065/74.6.543]
23 Carney JA,Stratakis CA.Familial paraganglioma and gastric stromal sarcoma:a new syndrome distinct from the Carney triad.Am J Med Genet 2002;108:132-139[PMID:11857563]
24 Corless CL,Barnett CM,Heinrich MC.Gastrointestinal stromal tumours:origin and molecular oncology.Nat Rev Cancer 2011;11:865-878[PMID:22089421 DOI:10.1038/nrc3143]
25 Janeway KA,Weldon CB.Pediatric gastrointestinal stromal tumor.Semin Pediatr Surg 2012;21:31-43[PMID:22248968DOI:10.1053/j.sempedsurg.2011.10.003]
26 Scarpa M,Bertin M,Ruffolo C,Polese L,D’Amico DF,Angriman I.A systematic review on the clinical diagnosis of gastrointestinal stromal tumors.J Surg Oncol 2008;98:384-392[PMID:18668671DOI:10.1002/jso.21120]
27 Kim JS,Kim HJ,Park SH,Lee JS,Kim AY,Ha HK.Computed tomography features and predictive findings of ruptured gastrointestinal stromal tumours.Eur Radiol 2017;27:2583-2590[PMID:27761711 DOI:10.1007/s00330-016-4515-z]
28 Levy AD,Remotti HE,Thompson WM,Sobin LH,Miettinen M.Gastrointestinal stromal tumors:radiologic features with pathologic correlation.Radiographics 2003;23:283-304,456;quiz 532[PMID:12640147 DOI:10.1148/rg.232025146]
29 Eisenhauer EA,Therasse P,Bogaerts J,Schwartz LH,Sargent D,Ford R,Dancey J,Arbuck S,Gwyther S,Mooney M,Rubinstein L,Shankar L,Dodd L,Kaplan R,Lacombe D,Verweij J.New response evaluation criteria in solid tumours:revised RECISTguideline(version 1.1).Eur J Cancer 2009;45:228-247[PMID:19097774 DOI:10.1016/j.ejca.2008.10.026]
30 Raut CP,Posner M,Desai J,Morgan JA,George S,Zahrieh D,Fletcher CD,Demetri GD,Bertagnolli MM.Surgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitors.J Clin Oncol 2006;24:2325-2331[PMID:16710031 DOI:10.1200/jco.2005.05.3439]
31 Choi H,Charnsangavej C,Faria SC,Macapinlac HA,Burgess MA,Patel SR,Chen LL,Podoloff DA,Benjamin RS.Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate:proposal of new computed tomography response criteria.J Clin Oncol 2007;25:1753-1759[PMID:17470865 DOI:10.1200/jco.2006.07.3049]
32 Choi H.Role of Imaging in Response Assessment and Individualised Treatment for Sarcomas.Clin Oncol(R Coll Radiol)2017;29:481-488[PMID:28506521 DOI:10.1016/j.clon.2017.04.002]
33 Koo HJ,Shin JH,Shin S,Yoon HK,Ko GY,Gwon DI.Efficacy and Clinical Outcomes of Transcatheter Arterial Embolization for Gastrointestinal Bleeding from Gastrointestinal Stromal Tumor.JVasc Interv Radiol 2015;26:1297-304.e1[PMID:26190186 DOI:10.1016/j.jvir.2015.06.005]
34 Eriksson M,Reichardt P,Sundby Hall K,Schütte J,Cameron S,Hohenberger P,Bauer S,Leinonen M,Reichardt A,Rejmyr Davis M,Alveg?rd T,Joensuu H.Needle biopsy through the abdominal wall for the diagnosis of gastrointestinal stromal tumour-Does it increase the risk for tumour cell seeding and recurrence?Eur J Cancer 2016;59:128-133[PMID:27033260 DOI:10.1016/j.ejca.2016.02.021]
35 Takaki H,Litchman T,Covey A,Cornelis F,Maybody M,Getrajdman GI,Sofocleous CT,Brown KT,Solomon SB,Alago W,Erinjeri JP.Hepatic artery embolization for liver metastasis of gastrointestinal stromal tumor following imatinib and sunitinib therapy.J Gastrointest Cancer 2014;45:494-499[PMID:25358551 DOI:10.1007/s12029-014-9663-2]
36 Kobayashi K,Gupta S,Trent JC,Vauthey JN,Krishnamurthy S,Ensor J,Ahrar K,Wallace MJ,Madoff DC,Murthy R,Mc Rae SE,Hicks ME.Hepatic artery chemoembolization for 110gastrointestinal stromal tumors:response,survival,and prognostic factors.Cancer 2006;107:2833-2841[PMID:17096432 DOI:10.1002/cncr.22336]
37 Pawlik TM,Vauthey JN,Abdalla EK,Pollock RE,Ellis LM,Curley SA.Results of a single-center experience with resection and ablation for sarcoma metastatic to the liver.Arch Surg 2006;141:537-43;discussion 543-4[PMID:16785353 DOI:10.1001/archsurg.141.6.537]
38 Papanikolaou IS,Triantafyllou K,Kourikou A,R?sch T.Endoscopic ultrasonography for gastric submucosal lesions.World J Gastrointest Endosc 2011;3:86-94[PMID:21772939 DOI:10.4253/wjge.v3.i5.86]
39 Tio TL,Tytgat GN,den Hartog Jager FC.Endoscopic ultrasonography for the evaluation of smooth muscle tumors in the upper gastrointestinal tract:an experience with 42 cases.Gastrointest Endosc 1990;36:342-350[PMID:2210274]
40 Ando N,Goto H,Niwa Y,Hirooka Y,Ohmiya N,Nagasaka T,Hayakawa T.The diagnosis of GI stromal tumors with EUS-guided fine needle aspiration with immunohistochemical analysis.Gastrointest Endosc 2002;55:37-43[PMID:11756912 DOI:10.1067/mge.2002.120323]
41 Watson RR,Binmoeller KF,Hamerski CM,Shergill AK,Shaw RE,Jaffee IM,Stewart L,Shah JN.Yield and performance characteristics of endoscopic ultrasound-guided fine needle aspiration for diagnosing upper GI tract stromal tumors.Dig Dis Sci 2011;56:1757-1762[PMID:21360279 DOI:10.1007/s10620-011-1646-6]
42 Demetri GD,Benjamin RS,Blanke CD,Blay JY,Casali P,Choi H,Corless CL,Debiec-Rychter M,De Matteo RP,Ettinger DS,Fisher GA,Fletcher CD,Gronchi A,Hohenberger P,Hughes M,Joensuu H,Judson I,Le Cesne A,Maki RG,Morse M,Pappo AS,Pisters PW,Raut CP,Reichardt P,Tyler DS,Van den Abbeele AD,von Mehren M,Wayne JD,Zalcberg J;NCCN Task Force.NCCN Task Force report:management of patients with gastrointestinal stromal tumor(GIST)--update of the NCCN clinical practice guidelines.JNatl Compr Canc Netw 2007;5 Suppl 2:S1-S29;quiz S30[PMID:17624289]
43 Kamiyama Y,Aihara R,Nakabayashi T,Mochiki E,Asao T,Kuwano H,Oriuchi N,Endo K.18F-fluorodeoxyglucose positron emission tomography:useful technique for predicting malignant potential of gastrointestinal stromal tumors.World J Surg 2005;29:1429-1435[PMID:16222452 DOI:10.1007/s00268-005-0045-6]
44 Van den Abbeele AD.The lessons of GIST--PET and PET/CT:a new paradigm for imaging.Oncologist 2008;13 Suppl 2:8-13[PMID:18434632 DOI:10.1634/theoncologist.13-S2-8]
45 Hassanzadeh-Rad A,Yousefifard M,Katal S,Asady H,FardEsfahani A,Moghadas Jafari A,Hosseini M.The value of(18)F-fluorodeoxyglucose positron emission tomography for prediction of treatment response in gastrointestinal stromal tumors:a systematic review and meta-analysis.J Gastroenterol Hepatol2016;31:929-935[PMID:26642423 DOI:10.1111/jgh.13247]
46 Everett M,Gutman H.Surgical management of gastrointestinal stromal tumors:analysis of outcome with respect to surgical margins and technique.J Surg Oncol 2008;98:588-593[PMID:19072850 DOI:10.1002/jso.21030]
47 Dematteo RP,Gold JS,Saran L,G?nen M,Liau KH,Maki RG,Singer S,Besmer P,Brennan MF,Antonescu CR.Tumor mitotic rate,size,and location independently predict recurrence after resection of primary gastrointestinal stromal tumor(GIST).Cancer2008;112:608-615[PMID:18076015 DOI:10.1002/cncr.23199]
48 Gold JS,Dematteo RP.Combined surgical and molecular therapy:the gastrointestinal stromal tumor model.Ann Surg2006;244:176-184[PMID:16858179 DOI:10.1097/01.sla.0000218080.94145.cf]
49 Koga T,Hirayama Y,Yoshiya S,Taketani K,Nakanoko T,Yoshida R,Minagawa R,Kai M,Kajiyama K,Akahoshi K,Maehara Y.Necessity for resection of gastric gastrointestinal stromal tumors≤20 mm.Anticancer Res 2015;35:2341-2344[PMID:25862898]
50 Balde AI,Chen T,Hu Y,Redondo N JD,Liu H,Gong W,Yu J,Zhen L,Li G.Safety analysis of laparoscopic endoscopic cooperative surgery versus endoscopic submucosal dissection for selected gastric gastrointestinal stromal tumors:a propensity scorematched study.Surg Endosc 2017;31:843-851[PMID:27492430DOI:10.1007/s00464-016-5042-3]
51 Novitsky YW,Kercher KW,Sing RF,Heniford BT.Long-term outcomes of laparoscopic resection of gastric gastrointestinal stromal tumors.Ann Surg 2006;243:738-745;discussion 745-747[PMID:16772777 DOI:10.1097/01.sla.0000219739.11758.27]
52 Milone M,Elmore U,Musella M,Parise P,Zotti MC,Bracale U,Di Lauro K,Manigrasso M,Milone F,Rosati R.Safety and efficacy of laparoscopic wedge gastrectomy for large gastrointestinal stromal tumors.Eur J Surg Oncol 2017;43:796-800[PMID:28132787 DOI:10.1016/j.ejso.2017.01.005]
53 Honda M,Hiki N,Nunobe S,Ohashi M,Kiyokawa T,Sano T,Yamaguchi T.Long-term and surgical outcomes of laparoscopic surgery for gastric gastrointestinal stromal tumors.Surg Endosc 2014;28:2317-2322[PMID:24566748 DOI:10.1007/s00464-014-3459-0]
54 Masoni L,Gentili I,Maglio R,Meucci M,D’Ambra G,Di Giulio E,Di Nardo G,Corleto VD.Laparoscopic resection of large gastric GISTs:feasibility and long-term results.Surg Endosc 2014;28:2905-2910[PMID:24879133 DOI:10.1007/s00464-014-3552-4]
55 Piessen G,Lefèvre JH,Cabau M,Duhamel A,Behal H,Perniceni T,Mabrut JY,Regimbeau JM,Bonvalot S,Tiberio GA,Mathonnet M,Regenet N,Guillaud A,Glehen O,Mariani P,Denost Q,Maggiori L,Benhaim L,Manceau G,Mutter D,Bail JP,Meunier B,Porcheron J,Mariette C,Brigand C;AFC and the FREGAT working group.Laparoscopic Versus Open Surgery for Gastric Gastrointestinal Stromal Tumors:What Is the Impact on Postoperative Outcome and Oncologic Results?Ann Surg 2015;262:831-9;discussion829-40[PMID:26583673 DOI:10.1097/sla.0000000000001488]
56 Bischof DA,Kim Y,Dodson R,Carolina Jimenez M,Behman R,Cocieru A,Blazer DG 3rd,Fisher SB,Squires MH 3rd,Kooby DA,Maithel SK,Groeschl RT,Clark Gamblin T,Bauer TW,Karanicolas PJ,Law C,Quereshy FA,Pawlik TM.Open versus minimally invasive resection of gastric GIST:a multiinstitutional analysis of short-and long-term outcomes.Ann Surg Oncol 2014;21:2941-2948[PMID:24763984 DOI:10.1245/s10434-014-3733-3]
57 Khoo CY,Goh BKP,Eng AKH,Chan WH,Teo MCC,Chung AYF,Ong HS,Wong WK.Laparoscopic wedge resection for suspected large(≥5 cm)gastric gastrointestinal stromal tumors.Surg Endosc 2017;31:2271-2279[PMID:27631317 DOI:10.1007/s00464-016-5229-7]
58 Qiu G,Wang J,Che X,He S,Wei C,Li X,Pang K,Fan L.Laparoscopic Versus Open Resection of Gastric Gastrointestinal Stromal Tumors Larger Than 5 cm:A Single-Center,Retrospective Study.Surg Innov 2017;24:582-589[PMID:28933252 DOI:10.1177/1553350617731402]
59 Crouthamel MR,Kaufman JA,Billing JP,Billing PS,Landerholm RW.Incidental gastric mesenchymal tumors identified during laparoscopic sleeve gastrectomy.Surg Obes Relat Dis 2015;11:1025-1028[PMID:26645488 DOI:10.1016/j.soard.2015.06.004]
60 Yuval JB,Khalaileh A,Abu-Gazala M,Shachar Y,Keidar A,Mintz Y,Nissan A,Elazary R.The true incidence of gastric GIST-a study based on morbidly obese patients undergoing sleeve gastrectomy.Obes Surg 2014;24:2134-2137[PMID:24965544DOI:10.1007/s11695-014-1336-5]
61 Chiappetta S,Theodoridou S,Stier C,Weiner RA.Incidental finding of GIST during obesity surgery.Obes Surg 2015;25:579-583[PMID:25596937 DOI:10.1007/s11695-015-1571-4]
62 Tabrizian P,Sweeney RE,Uhr JH,Nguyen SQ,Divino CM.Laparoscopic resection of gastric and small bowel gastrointestinal stromal tumors:10-year experience at a single center.J Am Coll Surg 2014;218:367-373[PMID:24559952 DOI:10.1016/j.jamcol lsurg.2013.11.029]
63 Nguyen SQ,Divino CM,Wang JL,Dikman SH.Laparoscopic management of gastrointestinal stromal tumors.Surg Endosc 2006;20:713-716[PMID:16502196 DOI:10.1007/s00464-005-0435-8]
64 Ihn K,Hyung WJ,Kim HI,An JY,Kim JW,Cheong JH,Yoon DS,Choi SH,Noh SH.Treatment Results of Small Intestinal Gastrointestinal Stromal Tumors Less than 10 cm in Diameter:AComparison between Laparoscopy and Open Surgery.J Gastric Cancer 2012;12:243-248[PMID:23346497 DOI:10.5230/jgc.2012.12.4.243]
65 Cai W,Wang ZT,Wu L,Zhong J,Zheng MH.Laparoscopically assisted resections of small bowel stromal tumors are safe and effective.J Dig Dis 2011;12:443-447[PMID:22118693 DOI:10.1111/j.1751-2980.2011.00536.x]
66 Tabrizian P,Nguyen SQ,Divino CM.Laparoscopic management and longterm outcomes of gastrointestinal stromal tumors.J Am Coll Surg 2009;208:80-86[PMID:19228508 DOI:10.1016/j.jam collsurg.2008.08.028]
67 Kukar M,Kapil A,Papenfuss W,Groman A,Grobmyer SR,Hochwald SN.Gastrointestinal stromal tumors(GISTs)at uncommon locations:a large population based analysis.J Surg Oncol 2015;111:696-701[PMID:25560251 DOI:10.1002/jso.23873]
68 Tai WC,Chuah SK,Lin JW,Chen HH,Huang HY,Kuo CM,Yi LN,Lee CM,Changchien CS,Hu TH.Colorectal mesenchymal tumors-from smooth muscle tumors to stromal tumors.Oncol Rep2008;20:1157-1164[PMID:18949416]
69 Amato A.Colorectal gastrointestinal stromal tumor.Tech Coloproctol 2010;14 Suppl 1:S91-S95[PMID:20967481 DOI:10.1007/s10151-010-0631-y]
70 Duffaud F,Meeus P,Bachet JB,Cassier P,Huynh TK,Boucher E,BouchéO,Moutardier V,le Cesne A,Landi B,Marchal F,Bay JO,Bertucci F,Spano JP,Stoeckle E,Collard O,Chaigneau L,Isambert N,Lebrun-Ly V,Mancini J,Blay JY,Bonvalot S.Conservative surgery vs.duodeneopancreatectomy in primary duodenal gastrointestinal stromal tumors(GIST):a retrospective review of 114 patients from the French sarcoma group(FSG).Eur J Surg Oncol 2014;40:1369-1375[PMID:24994075 DOI:10.1016/j.ejso.2014.04.011]
71 Shen C,Chen H,Yin Y,Chen J,Han L,Zhang B,Chen Z,Chen J.Duodenal gastrointestinal stromal tumors:clinicopathological characteristics,surgery,and long-term outcome.BMC Surg 2015;15:98[PMID:26276408 DOI:10.1186/s12893-015-0084-3]
72 Johnston FM,Kneuertz PJ,Cameron JL,Sanford D,Fisher S,Turley R,Groeschl R,Hyder O,Kooby DA,Blazer D 3rd,Choti MA,Wolfgang CL,Gamblin TC,Hawkins WG,Maithel SK,Pawlik TM.Presentation and management of gastrointestinal stromal tumors of the duodenum:a multi-institutional analysis.Ann Surg Oncol 2012;19:3351-3360[PMID:22878613 DOI:10.1245/s10434-012-2551-8]
73 Tien YW,Lee CY,Huang CC,Hu RH,Lee PH.Surgery for gastrointestinal stromal tumors of the duodenum.Ann Surg Oncol 2010;17:109-114[PMID:19841981 DOI:10.1245/s10434-009-0761-5]
74 Chok AY,Koh YX,Ow MY,Allen JC Jr,Goh BK.A systematic review and meta-analysis comparing pancreaticoduodenectomy versus limited resection for duodenal gastrointestinal stromal tumors.Ann Surg Oncol 2014;21:3429-3438[PMID:24854490DOI:10.1245/s10434-014-3788-1]
75 Colombo C,Ronellenfitsch U,Yuxin Z,Rutkowski P,Miceli R,Bylina E,Hohenberger P,Raut CP,Gronchi A.Clinical,pathological and surgical characteristics of duodenal gastrointestinal stromal tumor and their influence on survival:a multi-center study.Ann Surg Oncol 2012;19:3361-3367[PMID:22843188 DOI:10.1245/s10434-012-2559-0]
76 Wilkinson MJ,Fitzgerald JE,Strauss DC,Hayes AJ,Thomas JM,Messiou C,Fisher C,Benson C,Tekkis PP,Judson I.Surgical treatment of gastrointestinal stromal tumour of the rectum in the era of imatinib.Br J Surg 2015;102:965-971[PMID:25970743DOI:10.1002/bjs.9818]
77 Machlenkin S,Pinsk I,Tulchinsky H,Ziv Y,Sayfan J,Duek D,Rabau M,Walfisch S.The effect of neoadjuvant Imatinib therapy on outcome and survival after rectal gastrointestinal stromal tumour.Colorectal Dis 2011;13:1110-1115[PMID:21040362DOI:10.1111/j.1463-1318.2010.02442.x]
78 Fujimoto Y,Akiyoshi T,Konishi T,Nagayama S,Fukunaga Y,Ueno M.Laparoscopic sphincter-preserving surgery(intersphincteric resection)after neoadjuvant imatinib treatment for gastrointestinal stromal tumor(GIST)of the rectum.Int J Colorectal Dis 2014;29:111-116[PMID:24018650 DOI:10.1007/s00384-013-1769-7]
79 Pintor-Tortolero J,García JC,Cantero R.Transanal minimally invasive surgery approach for rectal GIST.Tech Coloproctol 2016;20:321-322[PMID:26892744 DOI:10.1007/s10151-016-1438-2]
80 Andtbacka RH,Ng CS,Scaife CL,Cormier JN,Hunt KK,Pisters PW,Pollock RE,Benjamin RS,Burgess MA,Chen LL,Trent J,Patel SR,Raymond K,Feig BW.Surgical resection of gastrointestinal stromal tumors after treatment with imatinib.Ann Surg Oncol 2007;14:14-24[PMID:17072676 DOI:10.1245/s10434-006-9034-8]
81 Bonvalot S,Eldweny H,Péchoux CL,Vanel D,Terrier P,Cavalcanti A,Robert C,Lassau N,Cesne AL.Impact of surgery on advanced gastrointestinal stromal tumors(GIST)in the imatinib era.Ann Surg Oncol 2006;13:1596-1603[PMID:16957966 DOI:10.1245/s10434-006-9047-3]
82 Bamboat ZM,De Matteo RP.Metastasectomy for gastrointestinal stromal tumors.J Surg Oncol 2014;109:23-27[PMID:24155153DOI:10.1002/jso.23451]
83 Ye YJ,Gao ZD,Poston GJ,Wang S.Diagnosis and multidisciplinary management of hepatic metastases from gastrointestinal stromal tumour(GIST).Eur J Surg Oncol 2009;35:787-792[PMID:19185444 DOI:10.1016/j.ejso.2009.01.003]
84 Sugarbaker PH.Sarcomatosis and Imatinib-Resistant GISTosis:Diagnosis and Therapeutic Options.Cytoreductive Surgery Perioperative Chemotherapy for Peritoneal Surface Malignancy Textbook and Video Atlas.1st ed.Woodbury,CT:Cine-Med Publishing,Inc,2012:127-136
85 Raut CP,Wang Q,Manola J,Morgan JA,George S,Wagner AJ,Butrynski JE,Fletcher CD,Demetri GD,Bertagnolli MM.Cytoreductive surgery in patients with metastatic gastrointestinal stromal tumor treated with sunitinib malate.Ann Surg Oncol 2010;17:407-415[PMID:19898902 DOI:10.1245/s10434-009-0784-y]
86 Gronchi A,Fiore M,Miselli F,Lagonigro MS,Coco P,Messina A,Pilotti S,Casali PG.Surgery of residual disease following molecular-targeted therapy with imatinib mesylate in advanced/metastatic GIST.Ann Surg 2007;245:341-346[PMID:17435538DOI:10.1097/01.sla.0000242710.36384.1b]
87 De Matteo RP,Maki RG,Singer S,Gonen M,Brennan MF,Antonescu CR.Results of tyrosine kinase inhibitor therapy followed by surgical resection for metastatic gastrointestinal stromal tumor.Ann Surg 2007;245:347-352[PMID:17435539DOI:10.1097/01.sla.0000236630.93587.59]
88 Bonvalot S,Cavalcanti A,Le Péchoux C,Terrier P,Vanel D,Blay JY,Le Cesne A,Elias D.Randomized trial of cytoreduction followed by intraperitoneal chemotherapy versus cytoreduction alone in patients with peritoneal sarcomatosis.Eur J Surg Oncol 2005;31:917-923[PMID:15975759 DOI:10.1016/j.ejso.2005.04.010]
89 De Matteo RP,Shah A,Fong Y,Jarnagin WR,Blumgart LH,Brennan MF.Results of hepatic resection for sarcoma metastatic to liver.Ann Surg 2001;234:540-547;discussion 547-548[PMID:11573047]
90 Turley RS,Peng PD,Reddy SK,Barbas AS,Geller DA,Marsh JW,Tsung A,Pawlik TM,Clary BM.Hepatic resection for metastatic gastrointestinal stromal tumors in the tyrosine kinase inhibitor era.Cancer 2012;118:3571-3578[PMID:22086856DOI:10.1002/cncr.26650]
91 Husted TL,Neff G,Thomas MJ,Gross TG,Woodle ES,Buell JF.Liver transplantation for primary or metastatic sarcoma to the liver.Am J Transplant 2006;6:392-397[PMID:16426326 DOI:10.1111/j.1600-6143.2005.01179.x]
92 Serralta AS,Sanjuan FR,Moya AH,Orbis FC,López-Andújar R,Pareja EI,Vila JC,Rayón M,Juan MB,Mir JP.Combined liver transplantation plus imatinib for unresectable metastases of gastrointestinal stromal tumours.Eur J Gastroenterol Hepatol2004;16:1237-1239[PMID:15489588]
93 Corless CL,Ballman KV,Antonescu CR,Kolesnikova V,Maki RG,Pisters PW,Blackstein ME,Blanke CD,Demetri GD,Heinrich MC,von Mehren M,Patel S,Mc Carter MD,Owzar K,De Matteo RP.Pathologic and molecular features correlate with long-term outcome after adjuvant therapy of resected primary GIstromal tumor:the ACOSOG Z9001 trial.J Clin Oncol 2014;32:1563-1570[PMID:24638003 DOI:10.1200/jco.2013.51.2046]
94 Reichardt P,Hogendoorn PC,Tamborini E,Loda M,Gronchi A,Poveda A,Sch?ffski P.Gastrointestinal stromal tumors I:pathology,pathobiology,primary therapy,and surgical issues.Semin Oncol 2009;36:290-301[PMID:19664490 DOI:10.1053/j.seminoncol.2009.06.002]
95 Lasota J,Miettinen M.Clinical significance of oncogenic KITand PDGFRA mutations in gastrointestinal stromal tumours.Histopathology 2008;53:245-266[PMID:18312355 DOI:10.1111/j.1365-2559.2008.02977.x]
96 Blay JY,Heinrich MC,Hohenberger P,Casali PG,Rutkowski P,Serrano-Garcia C,Jones RL,Hall KS,Eckardt JR,von Mehren M.A randomized,double-blind,placebo-controlled,phase III study of crenolanib in advanced or metastatic GIST patients bearing a D842V mutation in PDGFRA:The Creno GIST study.J Clin Oncol 2017;35:published online before print[DOI:10.1200/JCO.2017.35.15_suppl.TPS11080]
97 Hostein I,Faur N,Primois C,Boury F,Denard J,Emile JF,Bringuier PP,Scoazec JY,Coindre JM.BRAF mutation status in gastrointestinal stromal tumors.Am J Clin Pathol 2010;133:141-148[PMID:20023270 DOI:10.1309/ajcppckga2qgbj1r]
98 Janeway KA,Kim SY,Lodish M,NoséV,Rustin P,Gaal J,Dahia PL,Liegl B,Ball ER,Raygada M,Lai AH,Kelly L,Hornick JL;NIH Pediatric and Wild-Type GIST Clinic,O’Sullivan M,de Krijger RR,Dinjens WN,Demetri GD,Antonescu CR,Fletcher JA,Helman L,Stratakis CA.Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRAmutations.Proc Natl Acad Sci U S A 2011;108:314-318[PMID:21173220 DOI:10.1073/pnas.1009199108]
99 Ricci R.Syndromic gastrointestinal stromal tumors.Hered Cancer Clin Pract 2016;14:15[PMID:27437068 DOI:10.1186/s13053-016-0055-4]
100 Casali PG,Zalcberg J,Le Cesne A,Reichardt P,Blay JY,Lindner LH,Judson IR,Sch?ffski P,Leyvraz S,Italiano A,Grünwald V,Pousa AL,Kotasek D,Sleijfer S,Kerst JM,Rutkowski P,Fumagalli E,Hogendoorn P,Litière S,Marreaud S,van der Graaf W,Gronchi A,Verweij J;European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group,Italian Sarcoma Group,and Australasian Gastrointestinal Trials Group.Ten-Year Progression-Free and Overall Survival in Patients With Unresectable or Metastatic GI Stromal Tumors:LongTerm Analysis of the European Organisation for Research and Treatment of Cancer,Italian Sarcoma Group,and Australasian Gastrointestinal Trials Group Intergroup Phase III Randomized Trial on Imatinib at Two Dose Levels.J Clin Oncol 2017;35:1713-1720[PMID:28362562 DOI:10.1200/jco.2016.71.0228]
101 Sanchez Hidalgo JM,Rufian Pe?a S,Ciria Bru R,Naranjo Torres A,Mu?oz Casares C,Ruiz Rabelo J,Brice?o Delgado J.Gastrointestinal stromal tumors(GIST):a prospective evaluation of risk factors and prognostic scores.J Gastrointest Cancer 2010;41:27-37[PMID:19960278 DOI:10.1007/s12029-009-9102-y]
102 Rutkowski P,Nowecki ZI,Michej W,Debiec-Rychter M,Wo?niak A,Limon J,Siedlecki J,Grzesiakowska U,Kakol M,Osuch C,Polkowski M,G?uszek S,Zurawski Z,Ruka W.Risk criteria and prognostic factors for predicting recurrences after resection of primary gastrointestinal stromal tumor.Ann Surg Oncol 2007;14:2018-2027[PMID:17473953 DOI:10.1245/s10434-007-9377-9]
103 Miettinen M,Lasota J.Gastrointestinal stromal tumors:Pathology and prognosis at different sites.Semin Diagn Pathol 2006;23:70-83[PMID:17193820 DOI:10.1053/j.semdp.2006.09.001]
104 Joensuu H.Risk stratification of patients diagnosed with gastrointestinal stromal tumor.Hum Pathol 2008;39:1411-1419[PMID:18774375 DOI:10.1016/j.humpath.2008.06.025]
105 Hohenberger P,Ronellenfitsch U,Oladeji O,Pink D,Str?bel P,Wardelmann E,Reichardt P.Pattern of recurrence in patients with ruptured primary gastrointestinal stromal tumour.Br J Surg 2010;97:1854-1859[PMID:20730857 DOI:10.1002/bjs.7222]
106 Besana-Ciani I,Boni L,Dionigi G,Benevento A,Dionigi R.Outcome and long term results of surgical resection for gastrointestinal stromal tumors(GIST).Scand J Surg 2003;92:195-199[PMID:14582540 DOI:10.1177/145749690309200304]
107 De Matteo RP,Ballman KV,Antonescu CR,Corless C,Kolesnikova V,von Mehren M,Mc Carter MD,Norton J,Maki RG,Pisters PW,Demetri GD,Brennan MF,Owzar K;American College of Surgeons Oncology Group(ACOSOG)Intergroup Adjuvant GIST Study Team for the Alliance for Clinical Trials in Oncology.Long-term results of adjuvant imatinib mesylate in localized,highrisk,primary gastrointestinal stromal tumor:ACOSOG Z9000(Alliance)intergroup phase 2 trial.Ann Surg 2013;258:422-429[PMID:23860199 DOI:10.1097/SLA.0b013e3182a15eb7]
108 Dematteo RP,Ballman KV,Antonescu CR,Maki RG,Pisters PW,Demetri GD,Blackstein ME,Blanke CD,von Mehren M,Brennan MF,Patel S,Mc Carter MD,Polikoff JA,Tan BR,Owzar K;American College of Surgeons Oncology Group(ACOSOG)Intergroup Adjuvant GIST Study Team.Adjuvant imatinib mesylate after resection of localised,primary gastrointestinal stromal tumour:a randomised,double-blind,placebo-controlled trial.Lancet 2009;373:1097-1104[PMID:19303137 DOI:10.1016/s0140-6736(09)60500-6]
109 Casali PG,Le Cesne A,Poveda Velasco A,Kotasek D,Rutkowski P,Hohenberger P,Fumagalli E,Judson IR,Italiano A,Gelderblom H,Adenis A,Hartmann JT,Duffaud F,Goldstein D,Broto JM,Gronchi A,Dei Tos AP,Marréaud S,van der Graaf WT,Zalcberg JR,Litière S,Blay JY.Time to Definitive Failure to the First Tyrosine Kinase Inhibitor in Localized GI Stromal Tumors Treated With Imatinib As an Adjuvant:A European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Intergroup Randomized Trial in Collaboration With the Australasian Gastro-Intestinal Trials Group,UNICANCER,French Sarcoma Group,Italian Sarcoma Group,and Spanish Group for Research on Sarcomas.J Clin Oncol 2015;33:4276-4283[PMID:26573069 DOI:10.1200/jco.2015.62.4304]
110 Joensuu H,Eriksson M,Sundby Hall K,Hartmann JT,Pink D,Schütte J,Ramadori G,Hohenberger P,Duyster J,Al-Batran SE,Schlemmer M,Bauer S,Wardelmann E,Sarlomo-Rikala M,Nilsson B,Sihto H,Monge OR,Bono P,Kallio R,Vehtari A,Leinonen M,Alveg?rd T,Reichardt P.One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor:a randomized trial.JAMA 2012;307:1265-1272[PMID:22453568DOI:10.1001/jama.2012.347]
111 Joensuu H,Wardelmann E,Sihto H,Eriksson M,Sundby Hall K,Reichardt A,Hartmann JT,Pink D,Cameron S,Hohenberger P,AlBatran SE,Schlemmer M,Bauer S,Nilsson B,Kallio R,Junnila J,Vehtari A,Reichardt P.Effect of KIT and PDGFRA Mutations on Survival in Patients With Gastrointestinal Stromal Tumors Treated With Adjuvant Imatinib:An Exploratory Analysis of a Randomized Clinical Trial.JAMA Oncol 2017;3:602-609[PMID:28334365DOI:10.1001/jamaoncol.2016.5751]
112 von Mehren M,Joensuu H.Gastrointestinal Stromal Tumors.JClin Oncol 2018;36:136-143[PMID:29220298 DOI:10.1200/jco.2017.74.9705]
113 ESMO/European Sarcoma Network Working Group.Gastrointestinal stromal tumours:ESMO Clinical Practice Guidelines for diagnosis,treatment and follow-up.Ann Oncol2014;25 Suppl 3:iii21-iii26[PMID:25210085 DOI:10.1093/annonc/mdu255]
114 Poveda A,Martinez V,Serrano C,Sevilla I,Lecumberri MJ,de Beveridge RD,Estival A,Vicente D,RubióJ,Martin-Broto J.SEOM Clinical Guideline for gastrointestinal sarcomas(GIST)(2016).Clin Transl Oncol 2016;18:1221-1228[PMID:27896638DOI:10.1007/s12094-016-1579-9]
115 Duffaud F,Meeus P,Bertucci F,Delhorme JB,Stoeckle E,Isambert N,Bompas E,Gagniere J,BouchéO,Toulmonde M,Salas S,Blay JY,Bonvalot S;French Sarcoma Group.Patterns of care and clinical outcomes in primary oesophageal gastrointestinal stromal tumours(GIST):A retrospective study of the French Sarcoma Group(FSG).Eur J Surg Oncol 2017;43:1110-1116[PMID:28433494 DOI:10.1016/j.ejso.2017.03.017]
116 Miettinen M,Lasota J.Gastrointestinal stromal tumors:review on morphology,molecular pathology,prognosis,and differential diagnosis.Arch Pathol Lab Med 2006;130:1466-1478[PMID:17090188 DOI:10.1043/1543-2165(2006)130[1466:Gstrom]2.0.Co;2]
117 Rubin BP,Blanke CD,Demetri GD,Dematteo RP,Fletcher CD,Goldblum JR,Lasota J,Lazar A,Maki RG,Miettinen M,Noffsinger A,Washington MK,Krausz T;Cancer Committee,College of American Pathologists.Protocol for the examination of specimens from patients with gastrointestinal stromal tumor.Arch Pathol Lab Med 2010;134:165-170[PMID:20121601 DOI:10.1043/1543-2165-134.2.165]
118 Sánchez Hidalgo JM,Mu?oz Casares FC,Rufian Pe?a S,Naranjo Torres A,Ciria Bru R,Brice?o Delgado J,López Cillero P.[Gastrointestinal stromal tumors(GIST):factors predictive of survival after R0-cytoreduction].Rev Esp Enferm Dig 2007;99:703-708[PMID:18290694]
119 Belev B,Br?i?I,Prejac J,Golubi?ZA,Vrbanec D,Bo?ikov J,Aleri?I,Boban M,Razumovi?JJ.Role of Ki-67 as a prognostic factor in gastrointestinal stromal tumors.World J Gastroenterol 2013;19:523-527[PMID:23382631 DOI:10.3748/wjg.v19.i4.523]
120 Cananzi FC,Lorenzi B,Belgaumkar A,Benson C,Judson I,Mudan S.Prognostic factors for primary gastrointestinal stromal tumours:are they the same in the multidisciplinary treatment era?Langenbecks Arch Surg 2014;399:323-332[PMID:24413830DOI:10.1007/s00423-014-1160-3]
121 Vallb?hmer D,Marcus HE,Baldus SE,Brabender J,Drebber U,Metzger R,H?lscher AH,Schneider PM.Serosal penetration is an important prognostic factor for gastrointestinal stromal tumors.Oncol Rep 2008;20:779-783[PMID:18813818]
122 Dei Tos AP,Laurino L,Bearzi I,Messerini L,Farinati F;Gruppo Italiano Patologi Apparato Digerente(GIPAD);SocietàItaliana di Anatomia Patologica e Citopatologia Diagnostica/International Academy of Pathology,Italian division(SIAPEC/IAP).Gastrointestinal stromal tumors:the histology report.Dig Liver Dis2011;43 Suppl 4:S304-S309[PMID:21459336 DOI:10.1016/s1590-8658(11)60586-0]
123 West RB,Corless CL,Chen X,Rubin BP,Subramanian S,Montgomery K,Zhu S,Ball CA,Nielsen TO,Patel R,Goldblum JR,Brown PO,Heinrich MC,van de Rijn M.The novel marker,DOG1,is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status.Am JPathol 2004;165:107-113[PMID:15215166 DOI:10.1016/s0002-9440(10)63279-8]
124 Kang GH,Srivastava A,Kim YE,Park HJ,Park CK,Sohn TS,Kim S,Kang DY,Kim KM.DOG1 and PKC-θare useful in the diagnosis of KIT-negative gastrointestinal stromal tumors.Mod Pathol 2011;24:866-875[PMID:21358619 DOI:10.1038/modpathol.2011.11]
